New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
06:03 EDTAZN, WFMStocks with implied volatility below IV index mean; WFM AZN
Stocks with implied volatility below IV index mean; Whole Foods (WFM) 29, AstraZeneca (AZN) 21 according to iVolatility.
News For WFM;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
June 25, 2015
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
June 24, 2015
15:53 EDTWFMSunTrust identifies the most likely M&A activity in specialty retail
Subscribe for More Information
13:39 EDTWFMDCA reports 'systemic overcharging' for pre-packaged foods at Whole Foods
Subscribe for More Information
10:31 EDTWFMNew York probing Whole Foods over alleged overcharging, Daily News reports
New York City has launched a probe of Whole Foods Markets after an investigation conducted by the Department of Consumer Affairs found items for sale at its locations were labeled inaccurately, with many overcharging consumers, according to The Daily News. A Whole Foods spokesman said the company disagrees with the city's findings and is "vigorously defending" itself against the allegations, the report noted. Reference Link
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
June 18, 2015
07:36 EDTAZNReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
June 16, 2015
19:25 EDTWFMWal-Mart ranks high among millenials, Ad Age says
Subscribe for More Information
14:23 EDTAZNReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptos’ pipeline, and maintains an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use